Clinical Trial Update: Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial [Phase 2]

View source ↗

Summary

A Phase 2 randomized, open-label, non-inferiority trial comparing trifluridine/tipiracil plus fruquintinib versus trifluridine/tipiracil plus bevacizumab in ref…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Fruquintinib (fruquintinib)
• Lonsurf (trifluridine/tipiracil)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Refractory Metastatic Colorectal Cancer | Phase 2 | Status: NOT_YET_RECRUITING